SCHEMBL4352164

SCHEMBL4352164

CC(C)NC(=S)Nc1ccc(F)c(F)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 4/20 0.38
HPGD P15428 3/20 0.38
ALOX12 P18054 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
EPHX2 P34913 1/20 0.38
NPC1 O15118 1/20 0.37
NPSR1 Q6W5P4 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352145 0.81 LMNA (0.49) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4346771 0.77 POLB (0.51) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4344475 0.74 RAB9A (0.57) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4346925 0.73 ALDH1A1 (0.50) LMNAKMT2AALDH1A1ALOX12HTT
SCHEMBL4357795 0.73 LMNA (0.79) LMNAKMT2AALDH1A1ALOX12HTT
SCHEMBL6226388 0.73 ALDH1A1 (0.43) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4351728 0.72 LMNA (0.38) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4349755 0.72 MAOB (0.58) LMNAKMT2AALDH1A1HPGDHTT
SCHEMBL4355850 0.72 SMN1; SMN2 (0.58) LMNAKMT2AALDH1A1HPGDALOX12
SCHEMBL4352226 0.72 POLB (0.46) LMNAKMT2AALDH1A1HPGDALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 LMNA 3160/4885KMT2A 2096/4885ALDH1A1 2565/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 LMNA 3661/4885KMT2A 1254/4885ALDH1A1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.